{"id":200273,"date":"2026-03-29T07:16:00","date_gmt":"2026-03-29T11:16:00","guid":{"rendered":"https:\/\/testing.news-you-need.com\/index.php\/2026\/03\/29\/eli-lilly-to-sign-2-billion-deal-for-ai-drug-development-with-hong-kongs-insilico-medicine-ft-says\/"},"modified":"2026-03-29T07:55:12","modified_gmt":"2026-03-29T11:55:12","slug":"eli-lilly-to-sign-2-billion-deal-for-ai-drug-development-with-hong-kongs-insilico-medicine-ft-says","status":"publish","type":"post","link":"https:\/\/testing.news-you-need.com\/index.php\/2026\/03\/29\/eli-lilly-to-sign-2-billion-deal-for-ai-drug-development-with-hong-kongs-insilico-medicine-ft-says\/","title":{"rendered":"Eli Lilly to sign $2 billion deal for AI drug development with Hong Kong&#8217;s Insilico Medicine, FT says"},"content":{"rendered":"<p><a href=\"https:\/\/www.reuters.com\/business\/healthcare-pharmaceuticals\/eli-lilly-sign-2-billion-deal-ai-drug-development-with-hong-kongs-insilico-2026-03-29\/\">Eli Lilly to sign $2 billion deal for AI drug development with Hong Kong&#8217;s Insilico Medicine, FT says<\/a><\/p>\n<p><a href=\"https:\/\/www.reuters.com\/business\/healthcare-pharmaceuticals\/eli-lilly-sign-2-billion-deal-ai-drug-development-with-hong-kongs-insilico-2026-03-29\/\">https:\/\/www.reuters.com\/business\/healthcare-pharmaceuticals\/eli-lilly-sign-2-billion-deal-ai-drug-development-with-hong-kongs-insilico-2026-03-29\/<\/a><\/p>\n<p>Publish Date: <a href=\"publish_date]\">2026-03-29 07:16:00<\/a><\/p>\n<p>Source Domain: <a href=\"www.reuters.com\">www.reuters.com<\/a><\/p>\n<p>Here is a summary of the provided content in an unordered list:<\/p>\n<ul>\n<li><strong>Partnership Announcement<\/strong>: U.S. drugmaker Eli Lilly is preparing to sign a significant $2 billion agreement with Hong Kong-based biotech company Insilico Medicine. <\/li>\n<li><strong>Focus Area<\/strong>: The collaboration will involve leveraging Insilico Medicine&#8217;s artificial intelligence for drug discovery to develop and market a diabetes treatment.<\/li>\n<li><strong>Exclusive Rights<\/strong>: Eli Lilly is set to acquire exclusive rights to sell a GLP-1 drug for diabetes from Insilico Medicine.<\/li>\n<li><strong>Deal Structure<\/strong>: The agreement includes an upfront payment of $115 million and may reach over $2 billion if specific regulatory and sales milestones are met.<\/li>\n<li><strong>Industry Trend<\/strong>: This deal highlights a growing trend among pharmaceutical companies to use AI in research and development to enhance efficiency and comply with FDA directives to reduce animal testing.<\/li>\n<li><strong>Upcoming Announcement<\/strong>: The official deal announcement is anticipated later on Sunday.<\/li>\n<li><strong>Unavailable Comments<\/strong>: Neither Eli Lilly nor Insilico Medicine have responded to immediate requests for comment from Reuters as of the report date.<\/li>\n<\/ul>\n<p>If there are any specific questions on details not covered in this summary, please feel free to ask!<\/p>\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Eli Lilly to sign $2 billion deal for AI drug development with Hong Kong&#8217;s Insilico&#8230;<\/p>\n","protected":false},"author":1,"featured_media":200274,"comment_status":"closed","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"fifu_image_url":"https:\/\/www.reuters.com\/resizer\/v2\/BKJGPLP7ONM37FUUCH5TJEEA4Q.jpg?auth=029fb3340bf922c3c2c59b4cb3deb3ae02101aec0ec4396298234dd1f8766f4d&height=1005&width=1920&quality=80&smart=true","fifu_image_alt":"","footnotes":""},"categories":[14],"tags":[20],"class_list":["post-200273","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-artificial-intelligence","tag-artificial-intelligence"],"_links":{"self":[{"href":"https:\/\/testing.news-you-need.com\/index.php\/wp-json\/wp\/v2\/posts\/200273"}],"collection":[{"href":"https:\/\/testing.news-you-need.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/testing.news-you-need.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/testing.news-you-need.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/testing.news-you-need.com\/index.php\/wp-json\/wp\/v2\/comments?post=200273"}],"version-history":[{"count":1,"href":"https:\/\/testing.news-you-need.com\/index.php\/wp-json\/wp\/v2\/posts\/200273\/revisions"}],"predecessor-version":[{"id":200275,"href":"https:\/\/testing.news-you-need.com\/index.php\/wp-json\/wp\/v2\/posts\/200273\/revisions\/200275"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/testing.news-you-need.com\/index.php\/wp-json\/wp\/v2\/media\/200274"}],"wp:attachment":[{"href":"https:\/\/testing.news-you-need.com\/index.php\/wp-json\/wp\/v2\/media?parent=200273"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/testing.news-you-need.com\/index.php\/wp-json\/wp\/v2\/categories?post=200273"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/testing.news-you-need.com\/index.php\/wp-json\/wp\/v2\/tags?post=200273"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}